Jon P Butchar, PhD

College

College of Medicine

Department/Division

Internal Medicine

Academic Title

Res Asst Professor

Research Program

Leukemia Research

Research Interest

Infection, Leukemia, Lymphocytic, Chronic, B-Cell, tularemia, Cancer

As a member of the Leukemia Research Program at the OSUCCC – James, Jonathan Butchar, PhD, seeks to improve the efficacy of antibody therapy through his research.

His work brings together pathogenesis and tumor immunotherapy by studying interactions between Fc-gamma receptor and Toll-like receptor signaling.

One of Dr. Butchar’s recent research projects suggests that IFN-? can re-educate nurse-like cells to shift toward an effector-like state. It also revealed that therapies promoting local IFN-? production may be effective adjuvants for antibody therapy in chronic lymphocytic leukemia.

He has co-authored numerous articles published in well-respected media, including The Journal of Immunology, Journal of Biological Chemistry, Blood and Journal of Leukocyte Biology.

Office Location

385C Wiseman Hall

400 W 12th Ave, Columbus, OH 43210

614-366-0726

614-247-4575

Jon.Butchar@osumc.edu;butchar.2@osu.edu

Publications

Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia.

Buteyn NJ, Fatehchand K, Harrington BK, Henderson SE, Benson DM, Tridandapani S, Butchar JP, Dettorre GM, Byrd JC, Merchand-Reyes G, Santhanam R, Fang H, Carson WE, Vasu S, Gautam S, Mo X

Int Immunol in press 06/02/2018
Fluorescent nanodiamonds engage innate immune effector cells: A potential vehicle for targeted anti-tumor immunotherapy.

Suarez-Kelly LP, Campbell AR, Rampersaud IV, Bumb A, Wang MS, Butchar JP, Tridandapani S, Yu L, Rampersaud AA, Carson WE, Suarez-Kelly LP, Campbell AR, Rampersaud IV, Bumb A, Wang MS, Butchar JP, Tridandapani S, Yu L, Rampersaud AA, Carson WE 3rd

Nanomedicine 13 909-920 04/01/2017
Fluorescent nanodiamonds engage innate immune effector cells: A potential vehicle for targeted anti-tumor immunotherapy.

Suarez-Kelly LP, Campbell AR, Rampersaud IV, Bumb A, Wang MS, Butchar JP, Tridandapani S, Yu L, Rampersaud AA, Carson WE, Suarez-Kelly LP, Campbell AR, Rampersaud IV, Bumb A, Wang MS, Butchar JP, Tridandapani S, Yu L, Rampersaud AA, Carson WE 3rd

Nanomedicine 13 909-920 04/01/2017
Active hexose-correlated compound enhances extrinsic-pathway-mediated apoptosis of Acute Myeloid Leukemic cells.

Fatehchand K, Santhanam R, Shen B, Erickson EL, Gautam S, Elavazhagan S, Mo X, Belay T, Tridandapani S, Butchar JP

PLoS One 12 e0181729 01/01/2017
Interferon-? Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells.

Fatehchand K, McMichael EL, Reader BF, Fang H, Santhanam R, Gautam S, Elavazhagan S, Mehta P, Buteyn NJ, Merchand-Reyes G, Vasu S, Mo X, Benson DM, Blachly JS, Carson WE 3rd, Byrd JC, Butchar JP, Tridandapani S, Fatehchand K, McMichael EL, Reader BF, Fang H, Santhanam R, Gautam S, Elavazhagan S, Mehta P, Buteyn NJ, Merchand-Reyes G, Vasu S, Mo X, Benson DM Jr, Blachly JS, Carson WE, Byrd JC, Butchar JP, Tridandapani S

J Biol Chem 291 25656-25666 12/02/2016
Interferon-? Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells.

Fatehchand K, McMichael EL, Reader BF, Fang H, Santhanam R, Gautam S, Elavazhagan S, Mehta P, Buteyn NJ, Merchand-Reyes G, Vasu S, Mo X, Benson DM, Blachly JS, Carson WE 3rd, Byrd JC, Butchar JP, Tridandapani S, Fatehchand K, McMichael EL, Reader BF, Fang H, Santhanam R, Gautam S, Elavazhagan S, Mehta P, Buteyn NJ, Merchand-Reyes G, Vasu S, Mo X, Benson DM Jr, Blachly JS, Carson WE, Byrd JC, Butchar JP, Tridandapani S

J Biol Chem 291 25656-25666 12/02/2016
Reprogramming Nurse-like Cells with Interferon ? to Interrupt Chronic Lymphocytic Leukemia Cell Survival.

Gautam S, Fatehchand K, Elavazhagan S, Reader BF, Ren L, Mo X, Byrd JC, Tridandapani S, Butchar JP

J Biol Chem 291 14356-62 07/01/2016
NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.

Jaime-Ramirez AC, McMichael EL, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, LaPerle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri M, Lee RJ, Carson WE, Jaime-Ramirez AC, McMichael EL, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, LaPerle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri M, Lee RJ, Carson WE 3rd, Jaime-Ramirez AC, McMichael EL, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, La Perle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri MA, Lee RJ, Carson WE 3rd, Jaime-Ramirez AC, McMichael E, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, La Perle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri MA, Lee RJ, Carson WE 3rd

Cancer Immunol Res 4 323-336 04/01/2016
NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.

Jaime-Ramirez AC, McMichael EL, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, LaPerle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri M, Lee RJ, Carson WE, Jaime-Ramirez AC, McMichael EL, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, LaPerle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri M, Lee RJ, Carson WE 3rd, Jaime-Ramirez AC, McMichael EL, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, La Perle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri MA, Lee RJ, Carson WE 3rd, Jaime-Ramirez AC, McMichael E, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, La Perle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri MA, Lee RJ, Carson WE 3rd

Cancer Immunol Res 4 323-336 04/01/2016
Toll-like Receptor 4 Ligands Down-regulate Fc? Receptor IIb (Fc?RIIb) via MARCH3 Protein-mediated Ubiquitination.

Fatehchand K, Ren L, Elavazhagan S, Fang H, Mo X, Vasilakos JP, Dietsch GN, Hershberg RM, Tridandapani S, Butchar JP

J Biol Chem 291 3895-904 02/19/2016
Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fc? Receptor (Fc?R) Function.

Ren L, Campbell A, Fang H, Gautam S, Elavazhagan S, Fatehchand K, Mehta P, Stiff A, Reader BF, Mo X, Byrd JC, Carson WE, Butchar JP, Tridandapani S, Ren L, Campbell A, Fang H, Gautam S, Elavazhagan S, Fatehchand K, Mehta P, Stiff A, Reader BF, Mo X, Byrd JC, Carson WE 3rd, Butchar JP, Tridandapani S

J Biol Chem 291 3043-52 02/05/2016
Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fc? Receptor (Fc?R) Function.

Ren L, Campbell A, Fang H, Gautam S, Elavazhagan S, Fatehchand K, Mehta P, Stiff A, Reader BF, Mo X, Byrd JC, Carson WE, Butchar JP, Tridandapani S, Ren L, Campbell A, Fang H, Gautam S, Elavazhagan S, Fatehchand K, Mehta P, Stiff A, Reader BF, Mo X, Byrd JC, Carson WE 3rd, Butchar JP, Tridandapani S

J Biol Chem 291 3043-52 02/05/2016
Granzyme B expression is enhanced in human monocytes by TLR8 agonists and contributes to antibody-dependent cellular cytotoxicity.

Elavazhagan S, Fatehchand K, Santhanam V, Fang H, Ren L, Gautam S, Reader B, Mo X, Cheney C, Briercheck E, Vasilakos JP, Dietsch GN, Hershberg RM, Caligiuri M, Byrd JC, Butchar JP, Tridandapani S

J Immunol 194 2786-95 03/15/2015
Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.

Zhong Y, Dong S, Strattan E, Ren L, Butchar JP, Thornton K, Mishra A, Porcu P, Bradshaw JM, Bisconte A, Owens TD, Verner E, Brameld KA, Funk JO, Hill RJ, Johnson AJ, Dubovsky JA

J Biol Chem 290 5960-78 03/06/2015
Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.

Cheney CM, Stephens DM, Mo X, Rafiq S, Butchar J, Flynn JM, Jones JA, Maddocks K, O'Reilly A, Ramachandran A, Tridandapani S, Muthusamy N, Byrd JC

MAbs 6 749-55 05/01/2014
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.

Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R, Johnson AJ, Byrd JC

Blood 123 1957-60 03/20/2014
A novel immunomodulatory function of PHLPP1: inhibition of iNOS via attenuation of STAT1 ser727 phosphorylation in mouse macrophages.

Alamuru NP, Behera S, Butchar JP, Tridandapani S, Kaimal Suraj S, Babu PP, Hasnain SE, Ehtesham NZ, Parsa KV

J Leukoc Biol in press 01/17/2014
Monocyte/macrophage inflammatory response pathways to combat Francisella infection: possible therapeutic targets?

Gillette DD, Tridandapani S, Butchar JP

Front Cell Infect Microbiol 4 18 01/01/2014
Fc? receptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies.

Justiniano SE, Elavazhagan S, Fatehchand K, Shah P, Mehta P, Roda JM, Mo X, Cheney C, Hertlein E, Eubank TD, Marsh C, Muthusamy N, Butchar JP, Byrd JC, Tridandapani S

J Biol Chem 288 26800-9 09/13/2013
Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.

Rafiq S, Siadak A, Butchar JP, Cheney C, Lozanski G, Jacob NK, Lapalombella R, McGourty J, Moledor M, Lowe R, Setter B, Jones J, Flynn JM, Andritsos L, Devine S, Mo X, Jarjoura D, Tridandapani S, Algate P, Byrd JC, Muthusamy N

MAbs 5 723-35 09/01/2013

See Full List

Back to Researcher Search

Find a Researcher
Find a Clinical Trial

Please enter a keyword (i.e. Name, Research Interest) or choose a Research Program

By Name or Keyword

OR

By Research Program

Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator

Jon P Butchar, PhD

College

Department/Division

Academic Title

Research Program

Research Interest

Office Location

Publications

Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia.

Fluorescent nanodiamonds engage innate immune effector cells: A potential vehicle for targeted anti-tumor immunotherapy.

Fluorescent nanodiamonds engage innate immune effector cells: A potential vehicle for targeted anti-tumor immunotherapy.

Active hexose-correlated compound enhances extrinsic-pathway-mediated apoptosis of Acute Myeloid Leukemic cells.

Interferon-? Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells.

Interferon-? Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells.

Reprogramming Nurse-like Cells with Interferon ? to Interrupt Chronic Lymphocytic Leukemia Cell Survival.

NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.

NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.

Toll-like Receptor 4 Ligands Down-regulate Fc? Receptor IIb (Fc?RIIb) via MARCH3 Protein-mediated Ubiquitination.

Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fc? Receptor (Fc?R) Function.

Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fc? Receptor (Fc?R) Function.

Granzyme B expression is enhanced in human monocytes by TLR8 agonists and contributes to antibody-dependent cellular cytotoxicity.

Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.

Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.

Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.

A novel immunomodulatory function of PHLPP1: inhibition of iNOS via attenuation of STAT1 ser727 phosphorylation in mouse macrophages.

Monocyte/macrophage inflammatory response pathways to combat Francisella infection: possible therapeutic targets?

Fc? receptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies.

Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.

OR

OR

Search for Clinical Trials

Find a Scientific Publication

Jon P Butchar, PhD

College

Department/Division

Academic Title

Research Program

Research Interest

Office Location

Publications

Related Links

OR

OR

Search for Clinical Trials

Find a Scientific Publication